156 related articles for article (PubMed ID: 38706776)
1.
Krencz I; Sztankovics D; Sebestyén A; Pápay J; Dankó T; Moldvai D; Lutz E; Khoor A
Pathol Oncol Res; 2024; 30():1611593. PubMed ID: 38706776
[No Abstract] [Full Text] [Related]
2. Correlation between immunohistochemistry and RICTOR fluorescence in situ hybridization amplification in small cell lung carcinoma.
Krencz I; Sebestyen A; Papay J; Lou Y; Lutz GF; Majewicz TL; Khoor A
Hum Pathol; 2019 Nov; 93():74-80. PubMed ID: 31454632
[TBL] [Abstract][Full Text] [Related]
3. PD-L1 amplification is associated with an immune cell rich phenotype in squamous cell cancer of the lung.
Goldmann T; Marwitz S; Nitschkowski D; Krupar R; Backman M; Elfving H; Thurfjell V; Lindberg A; Brunnström H; La Fleur L; Mezheyeuski A; Mattsson JSM; Botling J; Micke P; Strell C
Cancer Immunol Immunother; 2021 Sep; 70(9):2577-2587. PubMed ID: 33576873
[TBL] [Abstract][Full Text] [Related]
4. Heterogeneity of Tumor and Immune Cell PD-L1 Expression and Lymphocyte Counts in Surgical NSCLC Samples.
Casadevall D; Clavé S; Taus Á; Hardy-Werbin M; Rocha P; Lorenzo M; Menéndez S; Salido M; Albanell J; Pijuan L; Arriola E
Clin Lung Cancer; 2017 Nov; 18(6):682-691.e5. PubMed ID: 28549836
[TBL] [Abstract][Full Text] [Related]
5. CD274/PD-L1 gene amplification and PD-L1 protein expression are common events in squamous cell carcinoma of the oral cavity.
Straub M; Drecoll E; Pfarr N; Weichert W; Langer R; Hapfelmeier A; Götz C; Wolff KD; Kolk A; Specht K
Oncotarget; 2016 Mar; 7(11):12024-34. PubMed ID: 26918453
[TBL] [Abstract][Full Text] [Related]
6. Correlation between RICTOR overexpression and amplification in advanced solid tumors.
Bang H; Ahn S; Ji Kim E; Kim ST; Park HY; Lee J; Kim KM
Pathol Res Pract; 2020 Jan; 216(1):152734. PubMed ID: 31740232
[TBL] [Abstract][Full Text] [Related]
7. The expression of PD-L1 protein as a prognostic factor in lung squamous cell carcinoma.
Takada K; Okamoto T; Toyokawa G; Kozuma Y; Matsubara T; Haratake N; Akamine T; Takamori S; Katsura M; Shoji F; Oda Y; Maehara Y
Lung Cancer; 2017 Feb; 104():7-15. PubMed ID: 28213003
[TBL] [Abstract][Full Text] [Related]
8. Expression of phosphatase and tensin homolog and programmed cell death ligand 1 in adenosquamous carcinoma of the lung.
Hlaing AM; Furusato B; Udo E; Kitamura Y; Souda M; Masutani M; Fukuoka J
Biochem Biophys Res Commun; 2018 Sep; 503(4):2764-2769. PubMed ID: 30100056
[TBL] [Abstract][Full Text] [Related]
9. Elucidation of the relationships of MET protein expression and gene copy number status with PD-L1 expression and the immune microenvironment in non-small cell lung cancer.
Yoshimura K; Inoue Y; Tsuchiya K; Karayama M; Yamada H; Iwashita Y; Kawase A; Tanahashi M; Ogawa H; Inui N; Funai K; Shinmura K; Niwa H; Suda T; Sugimura H
Lung Cancer; 2020 Mar; 141():21-31. PubMed ID: 31931443
[TBL] [Abstract][Full Text] [Related]
10. PD-L1 expression and its relationship with oncogenic drivers in non-small cell lung cancer (NSCLC).
Jiang L; Su X; Zhang T; Yin X; Zhang M; Fu H; Han H; Sun Y; Dong L; Qian J; Xu Y; Fu X; Gavine PR; Zhou Y; Tian K; Huang J; Shen D; Jiang H; Yao Y; Han B; Gu Y
Oncotarget; 2017 Apr; 8(16):26845-26857. PubMed ID: 28460468
[TBL] [Abstract][Full Text] [Related]
11. Prediction of Responsiveness to PD-L1/PD-1 Inhibitors Using miRNA Profiles Associated With PD-L1 Expression in Lung Adenocarcinoma and Squamous Cell Carcinoma.
Koh YW; Han JH; Haam S; Lee HW
Anticancer Res; 2024 May; 44(5):2081-2089. PubMed ID: 38677736
[TBL] [Abstract][Full Text] [Related]
12. Clinical significance of PD-L1 and PD-L2 copy number gains in non-small-cell lung cancer.
Inoue Y; Yoshimura K; Mori K; Kurabe N; Kahyo T; Mori H; Kawase A; Tanahashi M; Ogawa H; Inui N; Funai K; Shinmura K; Niwa H; Suda T; Sugimura H
Oncotarget; 2016 May; 7(22):32113-28. PubMed ID: 27050074
[TBL] [Abstract][Full Text] [Related]
13. Co-expression of IDO1 and PD-L1 in lung squamous cell carcinoma: Potential targets of novel combination therapy.
Takada K; Kohashi K; Shimokawa M; Haro A; Osoegawa A; Tagawa T; Seto T; Oda Y; Maehara Y
Lung Cancer; 2019 Feb; 128():26-32. PubMed ID: 30642449
[TBL] [Abstract][Full Text] [Related]
14. Altered expression of programmed death-ligand 1 after neo-adjuvant chemotherapy in patients with lung squamous cell carcinoma.
Song Z; Yu X; Zhang Y
Lung Cancer; 2016 Sep; 99():166-71. PubMed ID: 27565935
[TBL] [Abstract][Full Text] [Related]
15. A Clinicopathological and Prognostic Analysis of PD-L2 Expression in Surgically Resected Primary Lung Squamous Cell Carcinoma.
Matsubara T; Takada K; Azuma K; Takamori S; Toyokawa G; Haro A; Osoegawa A; Tagawa T; Kawahara A; Akiba J; Okamoto I; Nakanishi Y; Oda Y; Hoshino T; Maehara Y
Ann Surg Oncol; 2019 Jun; 26(6):1925-1933. PubMed ID: 30815803
[TBL] [Abstract][Full Text] [Related]
16. Morphometric analysis of nuclear shape irregularity as a novel predictor of programmed death-ligand 1 expression in lung squamous cell carcinoma.
Saito-Koyama R; Tamai K; Yasuda J; Okamura Y; Yamazaki Y; Inoue C; Miki Y; Abe J; Oishi H; Sato I; Sasano H
Virchows Arch; 2024 Apr; 484(4):609-620. PubMed ID: 37171482
[TBL] [Abstract][Full Text] [Related]
17. Evaluation of the programmed death-ligand 1 mRNA expression and immunopositivity and their correlation with survival outcomes in Indian lung cancer patients.
Kumar S; Pandey M; Mir IA; Mukhopadhyay A; Sharawat SK; Jain D; Saikia J; Malik PS; Kumar S; Mohan A
Hum Cell; 2022 Jan; 35(1):286-298. PubMed ID: 34786661
[TBL] [Abstract][Full Text] [Related]
18. PD-L1 Is Upregulated by Simultaneous Amplification of the PD-L1 and JAK2 Genes in Non-Small Cell Lung Cancer.
Ikeda S; Okamoto T; Okano S; Umemoto Y; Tagawa T; Morodomi Y; Kohno M; Shimamatsu S; Kitahara H; Suzuki Y; Fujishita T; Maehara Y
J Thorac Oncol; 2016 Jan; 11(1):62-71. PubMed ID: 26762740
[TBL] [Abstract][Full Text] [Related]
19. Rapamycin-insensitive companion of mTOR (RICTOR) amplification defines a subset of advanced gastric cancer and is sensitive to AZD2014-mediated mTORC1/2 inhibition.
Kim ST; Kim SY; Klempner SJ; Yoon J; Kim N; Ahn S; Bang H; Kim KM; Park W; Park SH; Park JO; Park YS; Lim HY; Lee SH; Park K; Kang WK; Lee J
Ann Oncol; 2017 Mar; 28(3):547-554. PubMed ID: 28028034
[TBL] [Abstract][Full Text] [Related]
20. An RNA-RNA crosstalk network involving HMGB1 and RICTOR facilitates hepatocellular carcinoma tumorigenesis by promoting glutamine metabolism and impedes immunotherapy by PD-L1+ exosomes activity.
Wei Y; Tang X; Ren Y; Yang Y; Song F; Fu J; Liu S; Yu M; Chen J; Wang S; Zhang K; Tan Y; Han Z; Wei L; Zhang B; Cheng Z; Li L; Wang H
Signal Transduct Target Ther; 2021 Dec; 6(1):421. PubMed ID: 34916485
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
